Objective-Transdifferentiation of adventitial fibroblasts (AFs) into myofibroblasts plays a critical role during the vascular remodeling that occurs during atherosclerosis, restenosis, and aortic aneurysm. The ubiquitination/deubiquitination regulatory system is essential for the quality control of proteins. The involvement of ubiquitination/deubiquitination during AF transdifferentiation remains largely unknown. In this study, we determined the role of cylindromatosis (CYLD), a deubiquitinase, in the process of AF differentiation and activation in vitro and in vivo. Approach and Results-Transforming growth factor-β1 and homocysteine, 2 known inducers of AF transdifferentiation, greatly upregulated CYLD expression in a time-and dose-dependent manner. The silencing of CYLD significantly inhibited AF transdifferentiation and activation as evidenced by the expression of contractile proteins, the production of the proinflammatory cytokines MCP-1 (monocyte chemotactic protein 1) and IL-6 (interleukin-6), the deposition of extracellular matrix, and cell migration. We further asked whether CYLD mediates AF activation via the regulation of nicotinamide adenine dinucleotide phosphate oxidase 4 (Nox4) as it is an essential factor during AF transdifferentiation. Indeed, the silencing of CYLD repressed transforming growth factor-β1-induced and homocysteine-induced Nox4 upregulation and reactive oxygen species production, whereas Nox4 overexpression greatly rescued the inhibitory effect on AF activation by CYLD silencing. Most interestingly, transforming growth factor-β1 and homocysteine repressed Nox4 ubiquitination and prolonged the half-life of Nox4. Moreover, Nox4 was deubiquitinated via a direct interaction with the ubiquitin-specific protease domain of CYLD. In accordance, hyperhomocysteinemia significantly increased adventitial CYLD and Nox4 expression, promoted AF transdifferentiation, and aggravated CaPO 4 -induced abdominal aortic aneurysm in mice. These effects were abolished in CYLD −/− mice. Conclusions-CYLD contributes to the transdifferentiation of AFs via deubiquitinating Nox4 and may play a role in vascular remodeling. Visual Overview-An online visual overview is available for this article.
C ompelling evidence has suggested that in response to stress or injury, adventitial cells are often the first to be activated and reprogrammed to influence the tone and structure of the vessel wall. 1, 2 Fibroblasts, the most abundant cell type in vascular adventitia, can undergo a phenotypic transition to myofibroblasts under certain circumstances. Once activated, the adventitial fibroblasts (AFs) exhibit an enhanced expression of contractile molecules, extracellular matrix proteins, and adhesion molecules. In addition, the activated AFs express a variety of cytokines/chemokines, growth factors, and reactive oxygen species (ROS) that exert paracrine and autocrine effects. [3] [4] [5] [6] The differentiation of AFs to myofibroblasts contributes to the alteration of vascular tone, to the initiation and perpetuation of chronic vascular inflammation, and to the expansion of the vasa vasorum. [7] [8] [9] Indeed, accumulating evidence has indicated that adventitial myofibroblasts are involved in the pathogenesis of atherosclerosis, restenosis, systemic and pulmonary hypertension, vein graft remodeling, and abdominal aortic aneurysm. 2, [7] [8] [9] Our recent studies also determined that hyperhomocysteinemia, an independent risk factor for cardiovascular diseases, promoted AF transdifferentiation and proinflammatory cytokine production and exaggerated abdominal aortic aneurysm in mice. 10, 11 Thus, elucidating the processes that control the phenotypic modulation of vascular fibroblasts is pivotal to understand the mechanisms of vascular remodeling in a variety of diseases. Previous studies have revealed the role of transforming growth factor-β (TGF-β), hypoxia, angiotension II, endothelin-1, IL (interleukin)-6, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (Nox4), and Fizzl in the phenotypic transition of fibroblasts to myofibroblasts. 10, [12] [13] [14] Our recent study also revealed that hyperhomocysteinemia transactivated AFs by upregulating Nox4. Nevertheless, the underlying mechanism of AF activation remains elusive.
The post-translational modification of different proteins by the ubiquitin-proteasome system is important for various cellular processes. This system is not only designed for target degradation and the quality control of damaged or misfolded proteins but is also essential in regulating a host of cell-signaling pathways involved in proliferation, adaptation to stress, the regulation of cell size, and cell death. Briefly, the mammalian ubiquitin-proteasome system is a cascade of enzymes that consists of 2 E1 (ubiquitin-activating enzymes), ≈30 E2 (ubiquitin-conjugating enzymes), and >1500 potential E3 (ubiquitin ligase) enzymes that target proteins for destruction by the proteasome. Ubiquitination is reversed by deubiquitination, which is accomplished by ≈100 deubiquitinating enzymes (DUBs). 15 The ubiquitination of the Notch, vascular endothelial growth factor, myocardin, FoxO1, and HIF-1α (hypoxia inducible factor-1α) signaling factors has been deemed pivotal for cardiovascular development and the progression of diseases including atherosclerosis, cardiac hypertrophy, and myocardial ischemia. [16] [17] [18] [19] [20] However, the involvement of ubiquitination/deubiquitination in the differentiation of AFs to myofibroblasts is still unknown.
Cylindromatosis (CYLD) is one of the best studied deubiquitinases, and it was initially identified as a tumor suppressor. Mutations in CYLD result in familial cylindromatosis. 21 To date, the role of CYLD in the pathogenesis of cardiovascular diseases remains elusive. Of interest are the results of limited studies that indicated that CYLD stimulates the migration of human umbilical vein endothelial cells and promotes an inflammatory response in vascular smooth muscle cells. 22, 23 Herein, we asked whether CYLD was involved in the phenotypic transition and activation of AFs. In this study, we found that CYLD induced the transdifferentiation of AFs by deubiquitinating Nox4 and in doing so might contribute to hyperhomocysteinemia-aggravated abdominal aortic aneurysm in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CYLD Mediates the Phenotypic Transition of AFs In Vitro
We first isolated primary aortic AFs and stimulated them with increasing amounts of TGF-β1 and homocysteine, both of which have been demonstrated to evoke fibroblast differentiation into myofibroblasts and activation, for various time periods. Indeed, we found a rapid induction of CYLD in AFs on treatment with TGF-β1 (as early as 10 minutes after treatment with 5 ng/mL) or pathological concentrations of homocysteine (as early as 5 minutes after treatment with 100 μmol/L; Figure  IA in the online-only Data Supplement). We also observed a dose-dependent upregulation of CYLD by TGF-β1 or homocysteine ( Figure IB in the online-only Data Supplement), indicating that CYLD may be involved in the differentiation of AFs to myofibroblasts. Next, we asked whether CYLD directly modulated the transdifferentiation of AFs or whether it just acted as a bystander. Because myofibroblasts are characterized by the expression of some contractile apparatuses such as α-actin, contractile markers were first examined in primary AFs stimulated with TGF-β1 or homocysteine. We firstly activated fibroblasts with various doses of TGF-β1 and homocysteine. As shown in Figure II in the onlineonly Data Supplement, TGF-β1 and homocysteine optimally upregulated α-actin and SM22α expression in AFs at 5 ng/ mL and 100 μmol/L, respectively. With these concentration, both TGF-β1 and homocysteine significantly induced CYLD expression, whereas both TGF-β1 and homocysteine stimulated expression of α-actin and SM22α, which was reversed by CYLD silencing but not by treatment with a scramble siRNA ( Figure 1A ). In addition to contractile proteins, myofibroblasts also exhibit an enhanced migratory ability. As a consequence, TGF-β1 and homocysteine significantly stimulated AF migration. CYLD siRNA, but not scramble siRNA, completely abolished the effect ( Figure 1B) . As previously reported, AF transdifferentiation and IL-6/MCP-1 (monocyte chemotactic protein 1) amplification loop accelerates vascular inflammation during hyperhomocysteinemia-aggravated abdominal aortic aneurysm (AAA) and aortic dissection in mice, respectively. 10, 24 Meanwhile, matrix protein production are compromised in AFs from patients with aneurysm. 25, 26 Thus, we also tested whether CYLD mediated the above process. As expected, TGF-β1 and homocysteine evoked proinflammatory cytokines MCP-1, IL-6, tumor necrosis factor-α, and IL-1β secretion. Interestingly, the elevated MCP-1 and IL-6 secretion was circumvented by CYLD inhibition ( Figure 1C ), whereas TGF-β1 and homocysteine-induced tumor necrosis factor-α and IL-1β secretion was not affected ( Figure IIIA in the online-only Data Supplement). Similarly, TGF-β1-evoked and homocysteine-evoked MCP-1 and IL-6 mRNA expression level was inhibited by CYLD inhibition ( Figure IIIB and IIIC in the online-only Data Supplement). Additionally, CYLD deficiency greatly repressed the TGF-β1-enhanced or homocysteine-enhanced production of matrix proteins, including collagen I, collagen III, and fibronectin in AFs ( Figure 1D ; Figure IIIC in the online-only Data Supplement). Together, our data suggested that CYLD mediated AF differentiation and activation in vitro. To further explore how TGF-β1 and homocysteine upregulated CYLD especially in short term, we measured mRNA levels of CYLD in AFs treated by TGF-β1 and homocysteine for different time points. TGF-β1 or homocysteine has no effect on CYLD mRNA expression until 6-hour treatment ( Figure IVA The data are expressed as mean±SEM from 3 independent experiments in duplicate. Two-way ANOVA, *P<0.05. B, Confluent adventitial fibroblast monolayers transfected with scramble or CYLD siRNA were scratch wounded 24 h after transfection. The cells were treated with transforming growth factor-β1 (TGF-β1; 5 ng/mL) or homocysteine (Hcy; 100 μmol/L) for an additional 12, 18, or 24 h before imaging (the dotted line indicates the wound edge). The migration distance is quantified in the bottom. Two-way ANOVA, *P<0.05 vs the scramble siRNA group at the same time point. C, IL-6 (interleukin-6) and MCP-1 (monocyte chemotactic protein 1 secretion levels in adventitial fibroblasts transfected with CYLD or scramble siRNA followed by treatment with TGF-β1 (5 ng/mL) or Hcy (100 μmol/L) for 48 h. Two-way ANOVA, *P<0.05, vs CTL with siRNAscramble. D, Interleukin-6, MCP-1, collagen I, collagen III, and fibronectin mRNA levels in adventitial fibroblasts transfected with CYLD or scramble siRNA followed by treatment with TGF-β1 (5 ng/mL) or Hcy (100 μmol/L) for 24 h. The data are expressed as the mean±SEM from 3 independent experiments in duplicate. Two-way ANOVA, *P<0.05, vs CTL with siRNAscramble. NS indicates no significance.
CYLD Promotes AF Transdifferentiation Into Myofibroblasts at Least in Part via NADPH Oxidase 4
AFs have been shown to produce substantial amounts of NADPH oxidase-derived ROS in response to vascular injury. 27, 28 Recent evidence indicates that the NAD(P)H oxidase homolog Nox4 accounts for most of the ROS-induced fibroblast activation and that it exerts an essential role in TGF-β1 signaling leading to fibroblast activation, differentiation into the myofibroblast phenotype, and matrix production. 29 Our recent study also suggests that Nox4-derived ROS mediates hyperhomocysteinemia-induced AF differentiation into myofibroblasts and MCP-1/IL-6 production during the formation of abdominal aortic aneurysms. 10 Therefore, we wondered whether CYLD regulates the activation of AFs via Nox4. We indeed observed a rapid upregulation of Nox4 in TGF-β1-stimulated and homocysteine-stimulated AFs after 15 minutes ( Figure 2A ). The silencing of CYLD, but not treatment with scramble siRNA, reversed the TGF-β1-induced and homocysteine-induced upregulation of Nox4. We also measured STAT3, phosphorylated STAT3, FoxO1, and phosphorylated FoxO1 protein levels in fibroblasts treated with TGF-β1/homocysteine because these proteins had been reported previously to take part in fibroblasts differentiation. 30 ,31 A 15-minute treatment with TGF-β1 or homocysteine had no effect on p-STAT3/STAT3 and p-FoxO1/FoxO1 levels in fibroblasts ( Figure 
CYLD Stabilizes Nox4 via Deubiquitination
To address how CYLD upregulated Nox4, we first measured the expression of the Nox4 protein in TGF-β1-stimulated or homocysteine-stimulated AFs at various time points. In line with the results from a previous study, we observed a rapid upregulation of Nox4 that began as early as 10 minutes and was sustained until 30 minutes after TGF-β1 or homocysteine stimulation ( Figure 3A) . Next, we assessed the level (transcriptional, post-transcriptional, translational, or posttranslational) at which Nox4 was regulated as quickly as 5 to 10 minutes in fibroblasts after the treatment with TGF-β1 or homocysteine. Of note, TGF-β1 and homocysteine did not induce Nox4 mRNA expression or affect the mRNA stability within the short time period (Figure VII in the onlineonly Data Supplement). Next, we applied cycloheximide and MG-132 to inhibit de novo protein synthesis and proteasomal degradation, respectively, in TGF-β1-treated or homocysteine-treated AFs. The stability of the Nox4 protein was markedly enhanced by stimulation with 5 ng/mL TGF-β1 or 100 μmol/L homocysteine starting from 10 minutes (CTL: 90.15±0.53% versus TGF-β1: 94.94±1.03%, P<0.05; CTL: 90.15±0.53% versus homocysteine: 95.73±0.80%, P<0.05; Figure 3B ). In addition, MG-132 ablated the difference in Nox4 expression between the TGF-β1/homocysteine and control treatments ( Figure 3C ), suggesting that degradation by the ubiquitin-proteasome affected the regulation of Nox4 in AFs. In accordance, a marked reduction in Nox4 ubiquitination was observed in TGF-β1/homocysteine-treated AFs ( Figure 3D ).
Considering that CYLD is a DUB, we next asked whether CYLD directly deubiquitinates Nox4. As shown in Figure 4A , coexpressing wild-type (WT)-CYLD, but not C/S-CYLD, a catalytically inactive C601S mutant, decreased the polyubiquitination of Nox4 in HEK293T cells. In accordance, the transfection of cells with pEGFP-CYLD, but not C/S-CYLD, markedly enhanced Nox4 protein levels ( Figure 4B ; Figure  VIII in the online-only Data Supplement).
We then determined whether CYLD affected TGF-β1-or homocysteine-repressed Nox4 polyubiquitination. Indeed, the silencing of CYLD reduced the homocysteine-induced and TGF-β1-induced suppression of Nox4 polyubiquitination in rat aortic AFs ( Figure 4C ). To test whether CYLD is the major deubiquitinase involved in the regulation of Nox4 in AFs, we also examined other DUBs that were reported to be pivotal in vascular cells. These included A20 (tumor necrosis factor-α-inducible protein), UCHL1 (ubiquitin carboxy-terminal esterase L1), and VDU2 (VHL proteininteracting DUB 2). In contrast to CYLD, the knockdown of A20, UCHL1, and VDU2 in primary AFs had no effect on TGF-β1-induced/homocysteine-induced Nox4 expression ( Figure IX in the online-only Data Supplement). Thus, Nox4 was specifically modulated by the DUB CYLD. Furthermore, we assessed the effect of CYLD on the polyubiquitination of endogenous Nox4 in HEK293T cells and found that overexpression of CYLD further decreased the TGF-β1-suppressed and homocysteine-suppressed ubiquitination of Nox4 ( Figure 4D ). Then, we overexpressed Nox4 in HEK293T and measured the polyubiquitination of exogenous Nox4 by CYLD. We found that overexpression of CYLD aggravated TGF-β1 and homocysteine-induced deubiquitination of Nox4, whereas knockdown of CYLD by pSUPER-CYLD shRNA plasmid reversed the effect of TGF-β1 and homocysteine on the ubiquitination of Nox4 ( Figure 4E ).
Because CYLD was reported that it has strong activity at lysine 63 (K63)-linked Ub chains but also showed activity at lysine 48 (K48)-linked Ub chains as well, 32, 33 we evaluated the role of K63-linked and K48-linked Ub chains and found that CYLD have the effect on both K63-and K48-linked Ub chains in the process of stabilizing Nox4 ( Figure X in the online-only Data Supplement). Taken together, these data suggested that CYLD could stabilize Nox4 via directly deubiquitinating Nox4.
NF-κB (nuclear factor-κB) signaling has been reported to mediate the upregulation of Nox4 related to inflammation in both vascular smooth muscle cells and ECs. 34, 35 We found TGF-β1-induced and homocysteine-induced nuclear translocation of NF-κB p65 in AFs as well, indicating the activation of NF-κB signaling ( Figure XIA in the online-only Data Supplement). Thus, we asked whether CYLD upregulated Nox4 via NF-κB signaling in AFs. As a result, parthenolide, the inhibitor of NF-κB signaling, had no effects on TGF-β1-increased and homocysteine-increased CYLD and Nox4 expressions ( Figure XIB) , implying that the CYLDupregulated Nox4 was independent of NF-κB signaling in AFs.
Direct Interaction Between CYLD and Nox4 Is Necessary for Nox4 Deubiquitination
Next, we examined whether CYLD physically interacts with Nox4 and determined the binding motif within CYLD. The results of the coimmunoprecipitation experiment in Figure 5A and 5B show that CYLD and Nox4 are indeed physically associated with each other in rat primary AFs, HEK293T cells, and COS7 cells coexpressing CYLD and Nox4. We then wondered which domain of CYLD directly interacted with Nox4. To answer this question, we transfected COS-7 cells infected with Ad-Nox4 adenovirus with Flag-tagged full-length CYLD or 2 Flag-tagged domains of CYLD including the domain spanning 3 Cap-Gly domains and the C-terminal ubiquitin-specific protease (USP) catalytic domain. 36 Only full-length CYLD and the USP domain coimmunoprecipitated with Nox4 ( Figure 5C ). Next, we asked whether interrupting the binding between CYLD and Nox4 affected Nox4 deubiquitination and expression. We subcloned the Flag-tagged C/S-USP fragment that could interact with Nox4 into COS-7 cells ( Figure 5D ). Transfection with Flagtagged C/S-USP fragment inhibited the interaction between endogenous Nox4 and CYLD ( Figure 5E ). Accordingly, the interruption of Nox4 and CYLD binding reversed the TGF-β1-inhibited and homocysteine-inhibited polyubiquitination of Nox4 ( Figure 5F ). Likewise, transfection with Flag-tagged C/S-USP fragment markedly reduced TGF-β1-induced and homocysteine-induced Nox4 protein expression ( Figure 5G ). Taken together, these data suggest that CYLD upregulates Nox4 by directly associating with and deubiquitinating Nox4.
CYLD Deficiency Abolishes the Hyperhomocysteinemia-Induced Nox4 Increase, AF Transdifferentiation, and Aggravated Abdominal Aortic Aneurysms in Mice
Hyperhomocysteinemia was an independent risk factor for a variety of cardiovascular diseases. Our previous work proved that hyperhomocysteinemia could aggravate angiotension II-induced aortic aneurysm by activating Nox4 in AFs. 10 To further determine the role of CYLD in vascular diseases in vivo, we used CYLD −/− mice and established a CaPO 4 -induced abdominal aortic aneurysm model in hyperhomocysteinemia mice. The mice were fed with homocysteine-supplemented water for 4 weeks and received surgery 14 days after the feeding began. There was no significant difference in body weight, blood pressure, and heart rate among these groups, but homocysteine administration successfully induced hyperhomocysteinemia in both WT and CYLD −/− mice ( Table I in the online-only Data Supplement). In line with our previous work, 10,11 CaPO 4 induction had no effect on plasma homocysteine levels of both genotypic mice, whereas both mice given homocysteine-supplemented water showed clinically relevant mild-to-moderate hyperhomocysteinemia in blood plasma Table I in the online-only Data Supplement). In agreement with the previous study, CaPO 4 induction significantly increased the expand of abdominal aorta in WT mice (maximal diameters of control versus CaPO4-treated 1.01±0.07, n=5 versus 1.39±0.23 mm, n=11; P=0.005), and the administration of homocysteine in water further aggravated the formation of aneurysms in the CaPO 4 -induced mouse model of aneurysm (maximal diameters of control versus homocysteine-fed: 1.39±0.23 mm, n=11 versus 1.64±0.23 mm, n=9; P=0.026). However, in CYLD-deficient mice, there was no significant difference in terms of the diameter between the hyperhomocysteinemia and control mice (maximal diameters of control versus homocysteine-fed: 1.14±0.18 mm, n=11 versus 1.02±0.14 mm, n=8; P=0.544) as shown in Figure 6A and 6B. Moreover, CYLD deficiency reversed the hyperhomocysteinemia-induced aggravation of elastin degradation in CaPO 4 -induced aortic media ( Figure 6C ). To determine whether the effect on aneurysms was because of the stabilization of Nox4 by CYLD in adventitia, we isolated the adventitia of infrarenal abdominal aortas. CaPO 4 treatment increased the expression of CYLD expression, paralleled with enhanced Nox4 protein level and contractile proteins in adventitia, and hyperhomocysteinemia further aggravated these effects induced by CaPO 4 in adventitia. However, the knockout of CYLD reversed the aggravation of CaPO 4 -induced Nox4 and contractile protein expression by hyperhomocysteinemia ( Figure 6D ). Because monocyte recruitment is also involved in adventitial pathology during aneurysm formation, 37 we measured the effect of CYLD on monocyte recruitment in vitro. The monocytes isolated from WT and CYLD −/− mice exhibited identical ability of migration in response to MCP-1 ( Figure XIIA in the online-only Data Supplement). Interestingly, the conditional medium from TGF-β1 or homocysteine-activated AFs significantly enhanced the monocytes migration, which was further reversed by CYLD silencing in fibroblasts ( Figure XIIB in the online-only Data Supplement). It indicated that CYLD derived from AFs, rather than monocytes, might contribute to monocytes recruitment via paracrine of chemotactic cytokines. In summary, the deubiquitinase CYLD mediated hyperhomocysteinemia-induced Nox4 upregulation, AF transdifferentiation, and aggravation of aneurysm formation in mice. 
Discussion
There had been compelling evidences that myofibroblastmediated adventitial remodeling, ROS production, and inflammation play pivotal roles in arterial pathology. However, the molecular mechanism of AF activation remains elusive. It has been established that the ubiquitination system finetunes protein degradation, signal transduction, and vascular homeostasis. Nevertheless, we know little about the role of ubiquitination in AF activation. Our data revealed that the deubiquitinase CYLD is an essential mediator of myofibroblast differentiation and, therefore, may serve as a therapeutic target for abdominal aortic aneurysm.
In the past decade, a new paradigm has emerged that adventitia can act as the principal injury-sensing tissue of the vessel wall and is capable of regulating vascular structure and function from the outside-in. 38 The fibroblast is the most abundant cell type in vascular adventitia and is often the first vascular wall cell to be activated during many common vascular diseases including atherosclerosis, restenosis, hypertension, aortic aneurysm, and dissection. The periadventitial inhibition of AF activation often results in the diminished formation of vascular lesions. 39, 40 Using S100A4 driven by Cre, a recent study revealed that fibroblast angiotensin II type 1a receptors contribute to angiotensin II-induced medial hyperplasia. 41 Our current study identified the deubiquitinase CYLD as a novel mediator of AF activation after stress. CYLD, which was originally identified as a tumor suppressor gene that is mutated in familial cylindromatosis, was determined to be a DUB that acts as a negative regulator of NF-κB and JNK signaling by removing Met1 and Lys63 chains from multiple NF-κB-signaling factors including NEMO, TRAF2, TRAF6, TRAF7, RIP1, and TAK1. [42] [43] [44] [45] Till now, the role of CYLD in vascular inflammation is conflict. CYLD was reported to inhibit inflammation through the inactivation of NF-κB and E2F 46 whereas also promote a proinflammatory response through the MAPK pathway. 47 This discrepancy might be because of the different signaling pathways and also indicates the complex effects of CYLD in different cells. Our data suggested that CYLD regulated fibroblast differentiation and subsequent aneurysmal pathology. The silencing of CYLD abolished TGF-β1-induced and homocysteine-induced AF transdifferentiation into myofibroblasts, oxidative stress, MCP-1/IL-6 secretion, and ECM production. Consequently, CYLD −/− mice exhibited repressed hyperhomocysteinemia-aggravated abdominal aortic aneurysm formation compared with their WT littermates. To the best of our knowledge, CYLD is the first DUB that regulates AF transdifferentiation and activation. A previous study suggested that CYLD is upregulated in human atherosclerosis lesions and experimental neointima hyperplasia on injury in rat carotid arteries. 46 Further in vivo studies are needed to clarify the importance of CYLD in the various cell types of the vessel wall and the effect of CYLD in vascular remodeling. Moreover, we identified that TGF-β1 and homocysteine significantly upregulated CYLD, especially in short term, via inhibiting ubiquitination and degradation. Previous study indeed suggested that SCFβ-TRCP regulated the ubiquitination and degradation of CYLD, a process dependent on prior phosphorylation of CYLD at Ser432/Ser436 by IKK. 48 The underlying mechanism of TGF-β1-inhibited and homocysteine-inhibited CYLD ubiquitination needs further investigation.
Another interesting finding of our study is the identification of CYLD as a Nox4 deubiquitinase. Nox4 is a member of the NADPH oxidase family and represents a major source of ROS in the vascular wall. AFs have been shown to produce substantial amounts of NADPH oxidase-derived ROS in response to vascular injury. Our previous study revealed that hyperhomocysteinemia upregulates Nox4 expression and exaggerates adventitial inflammation and angiotensin II-induced abdominal aortic aneurysm in mice. 10 Recent evidence also indicates that Nox4 is most responsible for ROS-induced fibroblast activation and differentiation in the heart and kidney, where it has an essential role in TGF-β1 signaling during cardiac and renal fibrosis. 49 Nevertheless, although elevated expression of Nox4 has been implicated in many cardiovascular diseases, including atherosclerosis, aortic aneurysm, pulmonary fibrosis, hypertension, cardiac failure, and ischemic stroke, 9,48-51 the role of Nox4 was context-dependent among these cardiovascular diseases. Nox4 has been reported to exhibit a protective effect on atherosclerosis, whereas it may facilitate lung fibrosis, cardiac failure, and aortic aneurysm. Till now, there was no direct evidence that adventitial Nox4 aggravated abdominal aortic aneurysm. However, Nox4 has been verified upregulated in human AAA segments and in angiotensin II-treated mouse aortas. 52 Recently, knockout of Nox4 was reported to have a protective effect on AAA in angiotensin II-infused hph-1 mice. 53 Thus, CYLD-deubiquitinated Nox4 may contribute to AAA formation. Unlike other NADPH homologues, Nox4 is truly unique, and the regulatory mechanism of Nox4 remains far from clear. Nox4 shows high constitutive activity and does not require the conventional cytoplasmic subunits p47 phox and p67 phox or its homologues for activation. 50 On the contrary, Nox4 is an inducible NADPH oxidase, and its expression level is dynamically regulated in response to a wide range of stimuli. Transcriptional regulation by NF-kB, Smad2/3, HIF1, Nrf2, and HDAC and posttranscriptional modulation by miRNA have been previously indicated for Nox4. [51] [52] [53] [54] [55] In contrast, the post-translational regulation of Nox4 is less understood. In particular, the fact that the rapid upregulation (within 5-15 minutes) of Nox4 has been repeatedly observed in TGF-β-stimulated myofibroblasts in the kidney, homocysteine-induced AFs in vessels, and insulin/high-glucose-stimulated human vascular smooth muscle cells and adipose cells 56, 57 cannot be explained by transcriptional regulation. Recently, SUMO1 (small ubiquitin-like modifier) was reported to suppress Nox4-derived H 2 O 2 . 58 However, evidence of the direct SUMOylation of Nox enzymes was not observed, suggesting an indirect interaction. Similarly, the glycosylation of Nox4 has been described, but digestion with glycosidase did not affect Nox4 expression or activity. The methylation of Nox4 has been excluded because protein methylation inhibitors did not influence Nox4-derived H 2 O 2 . Herein, we provide evidence of the post-translational regulation of Nox4 by deubiquitination. We demonstrate that CYLD directly binds to Nox4 via its USP domain and deubiquitinates Nox4, which is in line with the rapid enhancement of Nox4 in AFs. Of note, other DUBs such as A20, USP 20, and UCHL1, which have been reported to be pivotal in vascular cells, did not affect Nox4 expression in AFs, indicating the specific regulation of Nox4 by CYLD. The identification of the USP domain as the recognition site for Nox4 deubiquitination is in line with recent findings of structural and biochemical analyses of the CYLD USP domain. 59 Considering the importance of Nox4 in both health and disease, CYLD may be involved in the alteration of Nox4-related cellular signaling and function. As a DUB, CYLD showed activity at both K63 and K48-linked Ub chains. Although K48-linked Ub-chain could regulate the degradation of proteins, K63-linked Ub chain often affects the signaling like Akt, NF-κB. 60 Herein, we found that CYLD have the effect on both K48-and K63-linked UB chain in the process of stabilizing Nox4. The role of K63-linked Ub chain on Nox4 needs to further investigation.
In the present study, we identify CYLD as a critical regulator of Nox4-dependent fibroblast differentiation that acts, at least in part, by directly interacting with and deubiquitinating Nox4. An enhanced understanding of the mechanisms and molecular pathways responsible for AF differentiation, synthetic activity, and migration could lead to the development of novel strategies aimed at halting the progression of atherosclerosis, restenosis, and abdominal aortic aneurysm, etc. Thus, CYLD may serve as a novel target for vascular anti-inflammatory therapeutics to treat conditions such as the formation of abdominal aortic aneurysms.
